Pair page
IGF-1 LR3 with PEG-MGF
Mechanism-tag overlap and published literature for IGF-1 LR3 and PEG-MGF, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
igf-1-receptor-agonistlong-r3-analogmodified-protein
pegylated-igf-1-splice-variant
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying IGF-1 LR3 and PEG-MGF have published these mechanism-level observations. Not a co-administration recommendation.
PEG-MGF drives satellite cell activation; IGF-1 LR3 provides systemic anabolic IGF-1 signaling. Combination covers both recruitment of new myonuclei (PEG-MGF) and hypertrophy of existing fibers (LR3). Aggressive protocol with additive cancer, hypoglycemia, and cardiac risks. Entirely off-label; no safety characterization.
Quick facts
IGF-1 LR3
PEG-MGF
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2004 | IGF-1 LR3 | Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. (Epidemiologic IGF-1/cancer association.) | systematic review |
| 1999 | IGF-1 LR3 | Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. Horm Res. 1999;51(3):128-134. (Mecasermin European data.) | human study |
| 1993 | IGF-1 LR3 | Francis GL, Aplin SE, Milner SJ, McNeil KA, Ballard FJ, Wallace JC. Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II. Biochem J. 1993;… | mechanism / discovery |
| 1992 | IGF-1 LR3 | Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological poten… | mechanism / discovery |
| 1992 | IGF-1 LR3 | King R, Wells JR, Krieg P, Snoswell M, Brazier J, Bagley CJ, Wallace JC, Ballard FJ, Ross M, Francis GL. Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expre… | mechanism / discovery |
| 2026 | IGF-1 LR3 | WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. (All IGF-1 forms banned under S2.) | regulatory / registry |
| 2026 | IGF-1 LR3 | HHS Secretary Robert F. Kennedy Jr. Public Statement on Peptide Reclassification, February 27, 2026. (Reference for ongoing Category 2 → Category 1 review affecting IGF-1 family.) | regulatory / registry |
| 2025 | IGF-1 LR3 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025–2026. (IGF-1 LR3 Category 2 designation.) | regulatory / registry |
| 2005 | IGF-1 LR3 | Increlex (mecasermin) FDA Approval Documentation. FDA Approval Date: August 31, 2005. Sponsor: Tercica (now Ipsen). Indication: severe primary IGF-1 deficiency in children. (Native rhIGF-1; not IGF-1 LR3.) | regulatory / registry |
| — | IGF-1 LR3 | Thomas A, Solymos E, Schänzer W, Thevis M. Determination of insulin-like growth factor-I and IGF analogues in human serum by liquid chromatography-tandem mass spectrometry. (WADA detection methods for IGF-1 forms including LR3.) | regulatory / registry |
| — | IGF-1 LR3 | Ipsen Pharmaceuticals. Increlex (mecasermin) Prescribing Information. (FDA-approved native rhIGF-1; not IGF-1 LR3.) | regulatory / registry |
| 2009 | PEG-MGF | Riddoch-Contreras J, Yang SY, Dick JR, Goldspink G, Orrell RW, Greensmith L. Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) mice. Exp Neurol. 2009;215(2):281-289. PMID: 19056385. PMID 19056385 | preclinical, in vivo |
| 2005 | PEG-MGF | Shavlakadze T, Winn N, Rosenthal N, Grounds MD. Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth Horm IGF Res. 2005;15(1):4-18. PMID: 15701567. PMID 15701567 | preclinical, in vivo |
| 2003 | PEG-MGF | Hill M, Goldspink G. Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. J Physiol. 2003;549(Pt 2):409-418. PMID: 12692175. PMID 12692175 | preclinical, in vivo |
| 2002 | PEG-MGF | Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002;522(1-3):156-160. PMID: 12095634. PMID 12095634 | preclinical, in vitro |
| 2005 | PEG-MGF | Goldspink G. Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology (Bethesda). 2005;20:232-238. PMID: 16024702. (Foundational review of MGF / IGF-1Ec biology.) PMID 16024702 | review |
| 2026 | PEG-MGF | World Anti-Doping Agency. The 2026 Prohibited List. Montreal: WADA; 2026. (Class S2 prohibition — peptide hormones, growth factors, and mimetics including MGF analogs.) | regulatory / registry |
| 2015 | PEG-MGF | Yang Q, Lai SK. Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7(5):655-677. PMID: 25707913. (Anti-PEG antibody review relevant to chronic PEG-MGF exposure.) PMID 25707913 | research article |
| 2014 | PEG-MGF | Philippou A, Maridaki M, Pneumaticos S, Koutsilieris M. The complexity of the IGF1 gene splicing, posttranslational modification and bioactivity. Mol Med. 2014;20:202-214. PMID: 24637928. PMID 24637928 | research article |
| 2010 | PEG-MGF | Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl. 2010;49(36):6288-6308. PMID: 20648499. (PEG pharmacology including anti-PEG antibody context.) PMID 20648499 | research article |
| 2008 | PEG-MGF | Carpenter V, Matthews K, Devlin G, Stuart S, Jensen J, Conaglen J, Jeanplong F, Goldspink P, Yang SY, Goldspink G, Bass J, McMahon C. Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart Lung Circ. 2008;17(1):33-39. PMID: 17581797. PMID 17581797 | research article |
| 2007 | PEG-MGF | Mills P, Dominique JC, Lafrenière JF, Bouchentouf M, Tremblay JP. A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation success. Am J Transplant. 2007;7(10):2247-2259. PMID: 17845562. PMID 17845562 | research article |
| 2007 | PEG-MGF | Mills P, Lafrenière JF, Benabdallah BF, El Fahime el M, Tremblay JP. A new pro-migratory activity on human myogenic precursor cells for a synthetic peptide within the E domain of the mechano growth factor. Exp Cell Res. 2007;313(3):527-537. PMID: 17156777. PMID 17156777 | research article |
Related pair pages
More research context
Frequently asked
Have IGF-1 LR3 and PEG-MGF been studied together?
Researchers have published mechanistic-level co-administration discussion of IGF-1 LR3 and PEG-MGF. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do IGF-1 LR3 and PEG-MGF share?
IGF-1 LR3 and PEG-MGF do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of IGF-1 LR3 and PEG-MGF?
IGF-1 LR3: Research only (Category 2 bulk). PEG-MGF: Research only; no IND. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on IGF-1 LR3 and PEG-MGF?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the IGF-1 LR3 profile and the PEG-MGF profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026